Domestic & International
Dragon Pharma, Europe
Methyl-1-Test
Oral · 10 mg/tab · 100 tabs
$55.00
Compound ID
Methyl-1-Testosterone
Dosage
10–20 mg/day
Concentration
10 mg/tablet
Form
100 Tablets × 10 mg
Half-life
Approximately 5 hours
Properties
Shipping
Not available in this combination
Product overview
Dragon Pharma Methyl-1-Testosterone 10mg — Ultra-Potent Oral Anabolic for Rapid Dry Mass & Extreme Strength Amplification
Dragon Pharma Methyl-1-Testosterone 10mg occupies the apex of oral anabolic potency, a compound revered among advanced physique athletes as the most aggressively powerful tablet ever engineered for short-cycle hypertrophy. Structurally derived from dihydroboldenone and fortified with C17-alpha alkylation for oral bioavailability, this non-aromatizing androgen delivers dry, high-density tissue accretion and explosive strength surges within days of initiation. Unlike conventional mass builders that produce fluid-laden bulk, M1T generates lean, grainy muscularity characterized by exceptional hardness and minimal subcutaneous retention.
Dragon Pharma's precisely manufactured 10mg tablets have been independently verified at 10.98mg active content per unit, ensuring users receive a marginally overfilled, pharmaceutical-grade product capable of producing transformative results in remarkably brief timeframes—provided its severe hepatotoxic and suppressive profile is managed with absolute diligence.
What is Dragon Pharma Methyl-1-Testosterone?
Methyl-1-Testosterone, abbreviated as M1T, is a synthetic oral anabolic-androgenic steroid representing the 17-alpha-alkylated derivative of 1-testosterone (dihydroboldenone). The critical C17-aa structural modification enables the compound to survive first-pass hepatic metabolism, delivering exceptional oral bioavailability and systemic anabolic activity. Unlike many mass-building agents, M1T does not aromatize via the aromatase enzyme, eliminating estrogenic complications such as gynecomastia and water retention while producing characteristically dry, quality tissue gains.
Originally synthesized during the 1960s and later popularized during the prohormone era, this compound is not a prohormone precursor but rather a fully active steroid in its own right, exhibiting an anabolic potency that substantially exceeds classic orals such as Methandienone. Dragon Pharma's 10mg tablets provide the precise dosing granularity necessary for controlled administration of this formidable agent.
Key Benefits / Effects
- Unprecedented Rapid Hypertrophy: Users consistently report 10–15 pounds of lean tissue accretion within a 3–4 week cycle, representing the most aggressive short-term mass-building potential available in oral form.
- Explosive Strength Escalation: Compound lift performance frequently increases by 20–30% within the first 5–7 days, enabling personal record-breaking training intensity and neuromuscular overload.
- Exceptional Muscular Density: The non-aromatizing nature of the compound produces a dry, hard, and grainy aesthetic without the subcutaneous fluid accumulation that masks definition.
- Enhanced Nitrogen Retention: M1T creates a powerfully positive nitrogen balance, establishing the biochemical foundation necessary for rapid protein synthesis and tissue repair.
- Superior Glycogen Supercompensation: Intramuscular carbohydrate storage capacity expands dramatically, producing a full, pumped appearance even during non-training periods.
- Elevated Erythropoietic Activity: Stimulated red blood cell production improves oxygen-carrying capacity, supporting enhanced muscular endurance and faster inter-session recovery.
How Dragon Pharma Methyl-1-Testosterone Works
M1T initiates its effects through high-affinity binding to androgen receptors within skeletal myocytes, triggering genomic upregulation of muscle-specific protein synthesis, satellite cell activation, and myonuclear domain expansion. The compound's dihydroboldenone backbone confers strong anabolic character with reduced estrogenic liability, as the 1-ene structure and C17-aa modification prevent aromatase enzyme interaction. This creates a purely androgenic anabolic environment where nitrogen retention is maximized, glycogen storage is amplified, and catabolic hormone influence is minimized. Simultaneously, M1T stimulates erythropoietin release, increasing hematocrit and improving oxygen delivery to working tissues.
The C17-alpha alkylation, while essential for oral survival, introduces substantial hepatic metabolic burden that strictly limits cycle duration and necessitates aggressive organ protection protocols. The net physiological outcome is a rapid, dramatic shift toward anabolism that manifests visibly within the first week of administration.
Usage Information
Dragon Pharma Methyl-1-Testosterone is supplied as 10mg oral tablets and is reserved exclusively for advanced male athletes with extensive prior anabolic experience. Due to its extreme potency and hepatotoxicity, cycle duration must be strictly limited to 3–4 weeks maximum. Beginner M1T users should initiate at 10mg daily, typically administered as a single morning dose. Intermediate practitioners may employ 10–20mg daily, split into two administrations approximately 8 hours apart to maintain stable plasma concentrations.
Advanced users may briefly explore 20–30mg daily, though doses beyond this threshold produce exponentially increasing side effects with marginal additional anabolic returns. Female use is absolutely contraindicated under all circumstances due to rapid and irreversible virilization even at micro-doses. Oral administration with food may reduce gastrointestinal irritation. Comprehensive liver support, cardiovascular monitoring, and a testosterone base are mandatory throughout use. Post-Cycle Therapy must begin within 12–24 hours of the final dose.
Quality & Manufacturing
Dragon Pharma enforces uncompromising analytical and production standards, with each Methyl-1-Testosterone batch subjected to independent third-party laboratory verification for identity, purity, and potency. Recent analytical testing confirmed an actual M1T content of 10.98mg per tablet—representing 109.8% of the stated 10mg dose. This intentional overage policy reflects Dragon Pharma's commitment to ensuring users receive at minimum the full pharmacological payload required for predictable outcomes.
In the oral steroid marketplace, where underdosed and counterfeit products are endemic, this level of dosing accuracy is particularly critical for a compound of such extreme potency. A tablet falling short of its claim would fail to produce the legendary effects advanced users expect, while an unpredictably overdosed alternative could expose athletes to dangerous levels of hepatotoxicity and androgenic stress. Dragon Pharma's verified consistency provides the precision necessary for safe, effective administration.
Possible Side Effects / Safety Information
- Severe Hepatotoxicity: The C17-alpha alkylation necessary for oral bioavailability places extreme strain on hepatic enzyme systems. Even brief, moderate-dose cycles can produce dramatic transaminase elevations. Cycle length must not exceed 4 weeks, and aggressive liver support is mandatory.
- Profound HPTA Suppression: M1T rapidly and completely shuts down endogenous testosterone production, frequently causing severe lethargy, libido collapse, and mood disturbances during the cycle. A testosterone base and comprehensive PCT are non-negotiable.
- Intense Androgenic Manifestations: Users commonly experience severe acne, accelerated male pattern baldness in genetically predisposed individuals, and increased terminal hair growth due to the compound's high androgenic index.
- Extreme Cardiovascular Strain: M1T can produce significant blood pressure elevation and aggressively dyslipidemic shifts, including HDL depression and LDL elevation, necessitating vigilant cardiometabolic monitoring.
- Debilitating Lethargy: Many users report severe fatigue that impairs daily functioning, often becoming the primary limiting factor that forces early cycle termination.
- Gastrointestinal Disturbance: Appetite suppression, nausea, and general digestive discomfort are frequently reported, complicating the high caloric intake required to maximize anabolic potential.
- Sleep Disruption: Insomnia and night sweats similar to those associated with Trenbolone may occur, further compounding recovery challenges.
- Absolute Female Contraindication: Rapid and irreversible virilization—including voice deepening, clitoral enlargement, and hirsutism—occurs even at micro-doses; female use is categorically prohibited.
Why Choose Dragon Pharma Methyl-1-Testosterone?
When manipulating a compound of such extreme potency, product integrity becomes the paramount variable separating transformative results from dangerous uncertainty. Dragon Pharma's verified 10.98mg per tablet—delivering nearly 110% of the labeled claim—ensures that advanced athletes receive the full intended pharmacological impact without the guesswork of underdosed or counterfeit alternatives.
In a marketplace where M1T products are frequently mislabeled, contaminated, or dangerously inconsistent, this analytical transparency provides the confidence necessary to program short, intense cycles with mathematical precision. For experienced bodybuilders who have exhausted milder oral options and demand the absolute pinnacle of short-cycle anabolic power, Dragon Pharma Methyl-1-Testosterone represents a benchmark of manufacturing integrity in the service of extreme physiological transformation.
Better results than Oxandrolone, 30mg daily.
Excellent product quality...
Product FAQ
Questions, answered
M1T is among the fastest-acting oral anabolic agents available. Most users report noticeable strength increases, training aggression, and muscular fullness within 3–5 days of initiation. Visible hypertrophic changes and scale weight movement typically consolidate by the end of week one, with maximal results appearing during weeks 2–3. The rapid onset makes it ideal for short kickstart protocols or brief, intense mass phases.
The C17-alpha alkylation required for oral bioavailability imposes severe hepatic metabolic burden that accumulates rapidly. Beyond 3–4 weeks, liver enzyme elevations become increasingly likely and the risk-to-benefit ratio deteriorates catastrophically. Additionally, the profound suppression of natural testosterone production becomes debilitating for most users after several weeks, with lethargy and libido loss frequently forcing early termination. The compound is designed for brief, explosive use rather than sustained administration.
M1T generally produces more rapid and substantial dry mass gains than Methandienone, which carries significant water retention. Compared to Superdrol, M1T typically yields greater total weight accretion and strength enhancement, though Superdrol may produce a marginally drier aesthetic with somewhat less severe androgenic side effects. M1T's non-aromatizing nature eliminates estrogenic management concerns present with Dianabol, but its hepatotoxicity and suppression depth exceed both alternatives.
While not absolutely mandatory for very short 2-week cycles, a testosterone base is strongly recommended for any protocol exceeding 10–14 days. M1T's profound suppression rapidly depletes endogenous testosterone, producing severe low-androgen symptoms including lethargy, joint pain, erectile dysfunction, and depression. A base of 200–400mg weekly of Testosterone Enanthate or Cypionate maintains physiological androgen levels, preserving quality of life and training intensity while M1T drives rapid anabolic progress.
Given its extreme hepatotoxic potential, M1T requires the most aggressive liver support protocols available. Standard recommendations include TUDCA at 750–1000mg daily and N-acetylcysteine (NAC) at 1200–1800mg daily. Additional support may include milk thistle, Liv-52, or glutathione precursors. Complete alcohol abstinence is mandatory, as is avoidance of acetaminophen and all other hepatotoxic agents. Pre-cycle liver enzyme baselines must be established, with mid-cycle monitoring at day 10–14 to assess hepatic status.
No. Methyl-1-Testosterone does not aromatize to estrogen and possesses no progestogenic activity, eliminating the risk of gynecomastia, subcutaneous water retention, and estrogenic blood pressure elevation. The physique changes produced are characteristically dry, hard, and dense. However, users employing a testosterone base must still manage estrogen derived from the exogenous testosterone via aromatase inhibitors if necessary.
PCT must begin within 12–24 hours of the final M1T dose due to the depth of suppression. A comprehensive protocol includes Clomiphene Citrate at 50/50/25/25mg and Tamoxifen Citrate at 40/20/20/20mg over four weeks. For users who employed a testosterone base, PCT timing should account for ester clearance. HCG at 500–1000IU every other day for the two weeks preceding SERM initiation can prime testicular responsiveness. Blood work confirming recovered LH, FSH, and total testosterone should precede any subsequent cycle.
Stacking M1T with other C17-alpha alkylated orals is strongly discouraged and generally considered dangerous. The combined hepatotoxic burden from multiple 17-aa compounds can produce severe, potentially irreversible liver damage. If stacking is absolutely necessary, it should only involve non-alkylated injectable compounds such as Testosterone, Nandrolone, or Boldenone. Oral stacking should be reserved for experienced users under medical supervision with weekly liver monitoring.
Methyl-1-Testosterone possesses an androgenic potency and receptor affinity that produces rapid, irreversible virilization even at doses as low as 1–2mg daily. Female users would face near-certain development of voice deepening, clitoral enlargement, facial and body hair growth, and menstrual cessation within days of initiation. Unlike milder compounds where low-dose female protocols exist, M1T carries no safe therapeutic window for women and is categorically contraindicated.
Baseline panels must include total and free testosterone, estradiol, complete blood count, comprehensive metabolic panel with liver enzymes (ALT, AST, ALP, GGT, bilirubin), and a full lipid profile. Blood pressure should be monitored every 48–72 hours due to the compound's hypertensive potential. Mid-cycle testing at day 10–14 identifies emerging hepatic stress or dyslipidemia. Post-cycle panels at weeks 2 and 4 after cessation confirm hormonal recovery and metabolic normalization. These safeguards are non-negotiable for responsible use.
